TrialDiabetes, obesity & metabolism2026

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial.

What the trial testedrandomised · 172 people · 2026

Randomised comparison

−0.70percentage points−1.00 to −0.40

As reported

difference −0.7 %, 95% CI −1.00 to −0.40

the abstract, start to end

… 10 and 25 mg versus placebo were -0.7% (95% CI -1.0, -0.4; p <.0001) …

← favours treatmentfavours comparator →

could be chance

Glycemic control

−0.7−1.00 to −0.40

SGLT2 inhibitorsGlycemic control

SGLT2 inhibitors × glycemic controlhelps?replicated

unlikelylikely

0.920.92 without it

← favours treatmentfavours comparator →

this papermore certainless certain

1 / 5

2026

this papertrialcites it